The case for & against
Bull & Bear analysis
Bullish
Esperion Therapeutics (NASDAQ: ESPR) is a biotechnology company specializing in the development of cardiovascular therapies, particularly focusing on lipid-lowering treatments for patients with statin intolerance. Recently, ESPR completed its merger with Essence Parent Inc., becoming a wholly-owned subsidiary. This positioning, combined with its innovative therapeutic approach, places Esperion in a significant role within the growing cardiometabolic market.
Bull says
- ↑Q3 revenue +69% YoY to $87.3M
- ↑U.S. net product revenue $40.7M, up 31% YoY
- ↑Collaboration revenue jumped 128% to $46.7M
- ↑Cash and equivalents of $167.9M at Q4-end
- ↑Medicare approval rate 87% boosting patient access
- ↑Analysts’ average price target $5.54 signals upside
Bear says
- ↓Earnings yield remains negative and profitability weak
- ↓Operating expenses guided at $215M–$235M constrain FCF
- ↓Competition intensifies with new oral lipid therapies
- ↓Medicare Part D changes and higher out-of-pocket costs limit access
- ↓Regulatory and reimbursement uncertainties fuel investor skepticism
- ↓High leverage and negative revisions suggest risk sentiment
Investment themes with ESPR
Pharmaceuticals↓ -0.08%
Drug development driving global healthcare solutions
LLY · JNJ · MRK
Most Shorted Stocks↑ +0.54%
Stocks with highest short interest
LITE · FSLY · SPHR
Julian Komar's Best Winners (Screen Results)↓ -0.50%
NVDA · GOOGL · AVGO
Earnings Call · Q4 2024 · Mgmt. Guidance
Updated 07-14-2026bullish
Transcript signals
Bull points
- During 2024, we executed two transformational financial transactions that fundamentally reshaped our capital structure, providing us with enhanced operational and financial flexibility.
- In June 2024, we closed on a royalty purchase agreement with Omer's Life Sciences, receiving approximately $304.7 million in cash in exchange for 100% of our royalty interest from DSC royalty sales.
- Proceeds from the royalty purchase agreement facilitated early payout and termination of the Oberlin secured facility, removing all liens and covenants associated with that agreement.
Bear points
- Selling general and administrative expenses were $36.9 million compared to $45.4 million for the comparable period in 2023, a decrease of 19%, primarily related to increased legal litigation expenses reflecting one-time legal expenses from the legal resolution of the fourth quarter 2023.
- regarding recent prescription trends, I guess midway through 1Q here, we're seeing low single-digit growth, a step down from 4Q. Just curious, what is behind that trend?
Read full transcript analysis ›